Clinical trial · Interventional
Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas
NCT02547350CI-TRIAL-00019100unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy of prophylactic intravesical chemotherapy (different chemotherapy drugs and dosage regimen) in the prevention of bladder recurrence after nephroureterectomy for upper tract urothelial carcinoma (UTUC).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Recurrence | — | UNRESOLVED | — |
| Upper Tract Urothelial Carcinoma | Renal Pelvis and Ureter Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pharmorubicin or pirarubicin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- NO_INTERVENTION
- label
- Blank control
- description
- do not use prophylactic intravesical chemotherapy
- type
- EXPERIMENTAL
- label
- single intravesical instillation
- description
- intravesical instillation within 24 hours postoperatively
- interventionNames
- Drug: pharmorubicin or pirarubicin
- type
- EXPERIMENTAL
- label
- multiple intravesical instillation
- description
- intravesical instillation every 1 week for the first 2 months, then once a month for the rest 10 months
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients who were clinically diagnosed with UTUC 2. Treated with radical nephroureterectomy Exclusion Criteria: 1. Distant metastasis 2. Prior history of bladder or synchronous bladder cancer 3. Administration of neoadjuvant chemotherapy 4. Presence of severe complications.
References
Publications (0)
Data not yet available
No reference posted for this study.